Journal
MOLECULES
Volume 21, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/molecules21070927
Keywords
cancer; proteasome inhibitors; computer-aided drug design; virtual screening; molecular docking; pharmacophore model
Funding
- Fundacao para a Ciencia e Tecnologia [SFRH/BD/104441/2014, PTDC/QEQ-MED/7042/2014, UID/DTP/04138/2013]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/104441/2014, PTDC/QEQ-MED/7042/2014] Funding Source: FCT
Ask authors/readers for more resources
Proteasome emerged as an important target in recent pharmacological research due to its pivotal role in degrading proteins in the cytoplasm and nucleus of eukaryotic cells, regulating a wide variety of cellular pathways, including cell growth and proliferation, apoptosis, DNA repair, transcription, immune response, and signaling processes. The last two decades witnessed intensive efforts to discover 20S proteasome inhibitors with significant chemical diversity and efficacy. To date, the US FDA approved to market three proteasome inhibitors: bortezomib, carfilzomib, and ixazomib. However new, safer and more efficient drugs are still required. Computer-aided drug discovery has long being used in drug discovery campaigns targeting the human proteasome. The aim of this review is to illustrate selected in silico methods like homology modeling, molecular docking, pharmacophore modeling, virtual screening, and combined methods that have been used in proteasome inhibitors discovery. Applications of these methods to proteasome inhibitors discovery will also be presented and discussed to raise improvements in this particular field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available